| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Lymphoma Biology Section [K. B., G. S., M. W., J-G. J., I. M.] and Laboratory of Molecular Pharmacology [S. F., P. M. O.], National Cancer Institute, NIH, Bethesda, Maryland 20892
The growth arrest mediated by p53 is caused at least in part by the p53 mediated expression of p21 (p21waf1/Cip1). Since only one-third of primary Burkitt's lymphomas (BL) demonstrate mutations in the p53 gene, we examined the structural integrity of the p21 coding region by single-strand conformational polymorphism and DNA sequence analysis to determine the extent to which this gene is mutated in BL. Of 34 BLs analyzed, a frequent change (38%) at codon 31 that replaced Ser with Arg was found in 13 samples, 10 of which were from Africa. This change at codon 31 is also detected in peripheral blood DNA from normal subjects and may thus represent a polymorphism. One BL cell line, DH978, carried a change at codon 63: Phe to Leu. This mutation was heterozygous, and both the wild-type and the mutated p21 mRNA were expressed in the tumor cell line. By transfection experiments, the mutant p21 was less efficient in suppressing clonogenicity than wild-type p21. To our knowledge, this is the only mutation described in p21. The availability of this mutant p21 should further help in functional studies of p21.
1 To whom requests for reprints should be addressed, at Lymphoma Biology Section, Bldg. 10/13C205, National Cancer Institute, NIH, Bethesda, MD 20892.
Received 12/16/94. Accepted 2/17/95.
This article has been cited by other articles:
|
|
 |
|
  S. K. Agarwal, C. M. Mateo, and S. J. Marx Rare Germline Mutations in Cyclin-Dependent Kinase Inhibitor Genes in Multiple Endocrine Neoplasia Type 1 and Related States J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1826 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-G. Xi, K.-Y. Ding, X.-L. Su, D.-F. Chen, W.-C. You, Y. Shen, and Y. Ke p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions Carcinogenesis, November 1, 2004; 25(11): 2201 - 2206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Bellan, S Lazzi, G De Falco, A Nyongo, A Giordano, and L Leoncini Burkitt's lymphoma: new insights into molecular pathogenesis J. Clin. Pathol., March 1, 2003; 56(3): 188 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M J Schwerer, A Sailer, K Kraft, K Baczako, and H Maier Patterns of p21waf1/cip1 expression in non-papillomatous nasal mucosa, endophytic sinonasal papillomas, and associated carcinomas J. Clin. Pathol., November 1, 2001; 54(11): 871 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Gooch, R. E. Herrera, and D. Yee The Role of p21 in Interferon {{gamma}}-mediated Growth Inhibition of Human Breast Cancer Cells Cell Growth Differ., June 1, 2000; 11(6): 335 - 342. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Cinti, L. Leoncini, A. Nyongo, F. Ferrari, S. Lazzi, C. Bellan, R. Vatti, A. Zamparelli, G. Cevenini, G. M. T osi, et al. Genetic Alterations of the Retinoblastoma-Related Gene RB2/p130 Identify Different Pathogenetic Mechanisms in and among Burkitt’s Lymphoma Subtypes Am. J. Pathol., March 1, 2000; 156(3): 751 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Harima, K. Harima, S. Sawada, Y. Tanaka, S. Arita, and T. Ohnishi Loss of Heterozygosity on Chromosome 6p21.2 as a Potential Marker for Recurrence after Radiotherapy of Human Cervical Cancer Clin. Cancer Res., March 1, 2000; 6(3): 1079 - 1085. [Abstract] [Full Text]
|
|
|
|
|
|
P. P. McKenzie, S. M. Guichard, D. S. Middlemas, R. A. Ashmun, M. K. Danks, and L. C. Harris Wild-Type p53 Can Induce p21 and Apoptosis in Neuroblastoma Cells But the DNA Damage-induced G1 Checkpoint Function Clin. Cancer Res., December 1, 1999; 5(12): 4199 - 4207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Guedez, L. Courtemanch, and M. Stetler-Stevenson Tissue Inhibitor of Metalloproteinase (TIMP)-1 Induces Differentiation and an Antiapoptotic Phenotype in Germinal Center B Cells Blood, August 15, 1998; 92(4): 1342 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chin, J. Pomerantz, D. Polsky, M. Jacobson, C. Cohen, C. Cordon-Cardo, J. W. Horner II, and R. A. DePinho Cooperative effects of INK4a and ras in melanoma susceptibility in vivo Genes & Dev., November 1, 1997; 11(21): 2822 - 2834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Maestro, A. Gloghini, C. Doglioni, S. Piccinin, T. Vukosavljevic, D. Gasparotto, A. Carbone, and M. Boiocchi Human Non-Hodgkin's Lymphomas Overexpress a Wild-Type Form of p53 Which Is a Functional Transcriptional Activator of the Cyclin-Dependent Kinase Inhibitor p21 Blood, April 1, 1997; 89(7): 2523 - 2528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Qiu, H. J. Forman, A. H. Schonthal, and E. Cadenas Induction of p21 Mediated by Reactive Oxygen Species Formed during the Metabolism of Aziridinylbenzoquinones by HCT116 Cells J. Biol. Chem., December 13, 1996; 271(50): 31915 - 31921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Balbin, G. J. Hannon, A. M. Pendas, A. A. Ferrando, F. Vizoso, A. Fueyo, and C. Lopez-Otin Functional Analysis of a p21WAF1,CIP1,SDI1 Mutant (Arg94 right-arrow Trp) Identified in a Human Breast Carcinoma. EVIDENCE THAT THE MUTATION IMPAIRS THE ABILITY OF p21 TO INHIBIT CYCLIN-DEPENDENT KINASES J. Biol. Chem., June 28, 1996; 271(26): 15782 - 15786. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
